These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

901 related articles for article (PubMed ID: 28768735)

  • 1. Therapeutic strategies for spinal muscular atrophy: SMN and beyond.
    Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K;
    Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large animal model of spinal muscular atrophy and correction of phenotype.
    Duque SI; Arnold WD; Odermatt P; Li X; Porensky PN; Schmelzer L; Meyer K; Kolb SJ; Schümperli D; Kaspar BK; Burghes AH
    Ann Neurol; 2015 Mar; 77(3):399-414. PubMed ID: 25516063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spinal muscular atrophy.
    Vitte J; Attali R; Warwar N; Gurt I; Melki J
    Adv Exp Med Biol; 2009; 652():237-46. PubMed ID: 20225030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models.
    Hua Y; Liu YH; Sahashi K; Rigo F; Bennett CF; Krainer AR
    Genes Dev; 2015 Feb; 29(3):288-97. PubMed ID: 25583329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
    Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
    Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
    Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
    Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.
    Mattis VB; Butchbach ME; Lorson CL
    J Neurosci Methods; 2008 Oct; 175(1):36-43. PubMed ID: 18771690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing disease severity in symptomatic, Smn(-/-);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery.
    Glascock JJ; Osman EY; Wetz MJ; Krogman MM; Shababi M; Lorson CL
    Hum Gene Ther; 2012 Mar; 23(3):330-5. PubMed ID: 22029744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal muscular atrophy: from gene discovery to clinical trials.
    Nurputra DK; Lai PS; Harahap NI; Morikawa S; Yamamoto T; Nishimura N; Kubo Y; Takeuchi A; Saito T; Takeshima Y; Tohyama Y; Tay SK; Low PS; Saito K; Nishio H
    Ann Hum Genet; 2013 Sep; 77(5):435-63. PubMed ID: 23879295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving towards treatments for spinal muscular atrophy: hopes and limits.
    Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype.
    Hosseinibarkooie S; Peters M; Torres-Benito L; Rastetter RH; Hupperich K; Hoffmann A; Mendoza-Ferreira N; Kaczmarek A; Janzen E; Milbradt J; Lamkemeyer T; Rigo F; Bennett CF; Guschlbauer C; Büschges A; Hammerschmidt M; Riessland M; Kye MJ; Clemen CS; Wirth B
    Am J Hum Genet; 2016 Sep; 99(3):647-665. PubMed ID: 27499521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.
    Strathmann EA; Peters M; Hosseinibarkooie S; Rigo FW; Bennett CF; Zaworski PG; Chen KS; Nothnagel M; Wirth B
    PLoS One; 2018; 13(9):e0203398. PubMed ID: 30188931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy.
    Sleigh JN; Gillingwater TH; Talbot K
    Dis Model Mech; 2011 Jul; 4(4):457-67. PubMed ID: 21708901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
    Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect.
    Gavrilina TO; McGovern VL; Workman E; Crawford TO; Gogliotti RG; DiDonato CJ; Monani UR; Morris GE; Burghes AH
    Hum Mol Genet; 2008 Apr; 17(8):1063-75. PubMed ID: 18178576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.